These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1130 related items for PubMed ID: 12496364

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
    Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J.
    J Cell Sci; 2004 Apr 15; 117(Pt 10):2037-49. PubMed ID: 15054110
    [Abstract] [Full Text] [Related]

  • 4. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.
    Cancer Res; 2000 Apr 15; 60(8):2178-89. PubMed ID: 10786682
    [Abstract] [Full Text] [Related]

  • 5. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
    Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J.
    Oncogene; 2002 Oct 10; 21(46):7011-26. PubMed ID: 12370823
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells.
    Benndorf R, Böger RH, Ergün S, Steenpass A, Wieland T.
    Circ Res; 2003 Sep 05; 93(5):438-47. PubMed ID: 12881481
    [Abstract] [Full Text] [Related]

  • 7. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
    Jia H, Lohr M, Jezequel S, Davis D, Shaikh S, Selwood D, Zachary I.
    Biochem Biophys Res Commun; 2001 May 04; 283(2):469-79. PubMed ID: 11327725
    [Abstract] [Full Text] [Related]

  • 8. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS.
    J Pharmacol Exp Ther; 2001 Dec 04; 299(3):1073-85. PubMed ID: 11714897
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of retinal neovascularization by soluble EphA2 receptor.
    Chen J, Hicks D, Brantley-Sieders D, Cheng N, McCollum GW, Qi-Werdich X, Penn J.
    Exp Eye Res; 2006 Apr 04; 82(4):664-73. PubMed ID: 16359662
    [Abstract] [Full Text] [Related]

  • 12. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z.
    Cancer Res; 2001 Oct 01; 61(19):7002-8. PubMed ID: 11585724
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
    Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.
    Clin Cancer Res; 2002 Apr 01; 8(4):1242-50. PubMed ID: 11948139
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.
    Cancer Res; 2004 May 15; 64(10):3586-92. PubMed ID: 15150116
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.
    Cancer; 2000 Aug 01; 89(3):488-99. PubMed ID: 10931447
    [Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
    Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D.
    Cancer Res; 1996 Mar 15; 56(6):1324-30. PubMed ID: 8640821
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC, Scicli GM, McMahon G, Scicli AG.
    Microvasc Res; 2002 May 15; 63(3):304-15. PubMed ID: 11969307
    [Abstract] [Full Text] [Related]

  • 20. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T.
    Cancer Res; 2000 Dec 01; 60(23):6737-43. PubMed ID: 11118060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.